DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Eritoran
Eritoran
1 Combined Effect of Anti-High-Mobility Group Box-1 Monoclonal Antibody and Peramivir Against Influenza a Virus-Induced Pneumoni
Improving Pipeline for the Development of Influenza Antivirals
Hydrophobic Amino-Terminal Pocket CD14 Reveals a Bent Solenoid with a the Crystal Structure of Human Soluble
Advancing the Development Pipeline for the Treatment of Influenza
TLR4 Signaling Pathway Modulators As Potential Therapeutics in Inflammation and Sepsis
TLR4-Targeting Therapeutics: Structural Basis and Computer-Aided Drug Discovery Approaches
A Meeting Report from the 6Th Isirv Antiviral Group Conference T
Low-Dose Naltrexone/Acetaminophen
Antivirals - Influenza
Lipid and Lipoprotein Dysregulation in Sepsis: Clinical and Mechanistic Insights Into Chronic Critical Illness
The Preventive Treatment of Migraine with Low-Dose Naltrexone And
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients with Severe Sepsis the ACCESS Randomized Trial
For Print (17KB)
(TLR4) Antagonist Eritoran Tetrasodium Attenuates Liver Ischemia and Reperfusion Injury Through Inhibition of High-Mobility Group Box Protein B1 (HMGB1) Signaling
Eritoran Suppresses Colon Cancer by Altering a Functional Balance in Toll-Like Receptors That Bind Lipopolysaccharide
Novel Antiviral Therapies for Influenza and Other Respiratory Viruses Jennifer L
JPS Vol65 Supplement2 2015.Pdf
Eritoran: the Evidence of Its Therapeutic Potential in Sepsis Shahzad G
Top View
Drugs to Cure Avian Influenza Infection &Ndash
Influenza Virus-Induced Lung Injury: Pathogenesis and Implications for Treatment
Targeting TLR4 Signaling to Blunt Viral-Mediated Acute Lung Injury
Fecal Microbiota Transplant Rescues Mice from Sepsis Due to Multi-Drug Resistant Healthcare Pathogens by Restoring Systemic Immunity
Adjuvent and New Therapeutic Interventions in Septic Shock ?
Morphine Activates Neuroinflammation in a Manner Parallel to Endotoxin
Directed Self-Assembly of Herbal Small Molecules Into Sustained Release Hydrogels for Treating Neural Inflammation
Antiviral and Immunomodulatory Effects of Phytochemicals
This Thesis Has Been Submitted in Fulfilment of the Requirements for a Postgraduate Degree (E.G
Drug Does Not Significantly Reduce Risk of Death Among Patients with Severe Sepsis 19 March 2013
Novel Strategies for Targeting Innate Immune Responses to Influenza
Clinical Research Protocol
The TLR4 Antagonist Eritoran Protects Mice from Lethal Influenza Infection
Computationally Designed Bispecific MD2/CD14 Binding Peptides Show TLR4 Agonist Activity
(12) United States Patent (10) Patent No.: US 9,132,141 B2 Vogel Et Al
Clinical Experience with the Endotoxin Activity Assay Alexander D Romaschin*, David J Klein and John C Marshall
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients with Severe Sepsis the ACCESS Randomized Trial
Sepsis Study Failure Highlights Need for Trial Design Rethink
Download Special Issue
W. Joost Wiersinga Christopher W. Seymour Editors
Crystal Structure of the TLR4-MD-2 Complex with Bound Endotoxin Antagonist Eritoran